XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
81.82
+0.53 (+0.66%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close81.29
Open81.11
Bid0.00 x 0
Ask0.00 x 0
Day's Range80.79 - 81.87
52 Week Range58.66 - 88.98
Volume3,440,974
Avg. Volume3,873,633
Net Assets3.97B
NAV83.30
PE Ratio (TTM)N/A
Yield0.22%
YTD Return40.86%
Beta (3y)1.64
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Barrons.com18 hours ago

    Biotech: Lean in on the Pullback

    Investors have cooled on biotechnology stocks, taking some money off the table after enjoying a greater than 25% gain year-to-date through the end of September. Biotech mutual funds and exchange-traded ...

  • Barrons.com4 days ago

    For the Love of Biotech, Know What You Own

    Don't judge an exchange-traded fund by its cover -- obvious advice, but apparently not obvious enough. The SPDR S&P Biotech ETF (XBI) has returned 42% so far this year, more than double that of the iShares ...

  • ETF Trends11 days ago

    Biotech Slump Could be a Buying Opportunity

    Biotechnology stocks and ETFs are slumping in the fourth quarter. For example, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR ...

  • How Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill
    Investor's Business Daily11 days ago

    How Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill

    Biotech and pharma stocks dipped after the Senate's GOP tax reform leaves the fate of a key tax credit up in the air.

  • Barrons.com15 days ago

    Biotech: You Really, Really Don't Like Me

    Biotechnology fund outflows persist. For the week ended Nov. 29, biotechnology mutual funds and exchange-traded funds saw outflows of some $329 million, according to Lipper/AMG Data Services, which tracks ...

  • Bet on Biogen Inc for Easy Profits Into the New Year
    InvestorPlace25 days ago

    Bet on Biogen Inc for Easy Profits Into the New Year

    Biotech stocks have been a political football for over a year. Biogen Inc (NASDAQ:BIIB) stock managed to still be up almost 10% year-to-date. While BIIB stock has a high face value of $310 per share, it is not expensive.

  • Barrons.com26 days ago

    Biotech: What You Don't Know…And What You Don't Know You Don't Know…Could Hurt You

    It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success one day in the future. Just because someone wearing a lab coat makes a breakthrough, doesn’t necessarily mean a blockbuster drug is on the horizon. Years can pass before it’s clear whether an experimental treatment will generate returns for a drug maker.

  • Barrons.com29 days ago

    Easy Come, Easy Go: Biotech's Fading Flows

    Investors appear to be hitting the snooze button on biotechnology stocks. Net flows are slowing after seeing two consecutive weeks of fresh money. Biotech fund flows, including mutual funds and exchange-traded funds, were essentially flat for the week ended Nov. 15.

  • Investopedia29 days ago

    Biotech Funds Flashing Sell Signals

    Biotech funds are testing mid-year breakouts after selling off to two-month lows and could break down in coming weeks.

  • ETF Trendslast month

    Biotech Decline Could be a Buying Opportunity

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI) tumbled on Tuesday, extending losses that have ...

  • Investopedialast month

    Top 3 Healthcare ETFs for 2017

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
    Investor's Business Dailylast month

    Biotechs Sell Off In Droves — Are Investors Seeking Mergers?

    Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.

  • Benzingalast month

    Latest Tax Reform Bill From Senate GOP Seeks Repeal Of ACA Individual Mandate

    The latest Republican tax reform bill takes yet another stab at the Affordable Care Act with a proposed repeal of individual mandates, party leadership said Tuesday . The mandates had required Americans ...

  • Barrons.comlast month

    Biotech: Go With the Flow

    Fresh money marched into biotechnology stock mutual funds and exchange-traded funds for the week ended Nov. 8,  the second consecutive week of net inflows in the past six weeks, according to Lipper/AMG data. About $62 million flowed into 100 funds with some $58.7 billion in assets collectively. Flows are critical to biotech stock strength, according to Raymond James analyst Laura Chico. "In our view, biotech strength will likely be driven in part by specialist funds," she said in note published Thursday.

  • Buy Allergan Plc Ordinary Shares After the Earnings!
    InvestorPlacelast month

    Buy Allergan Plc Ordinary Shares After the Earnings!

    To say that Allergan Plc Ordinary Shares (NYSE:AGN) has had a bad second half of the summer is an understatement. Coming into this earnings report, and since its last earnings report in July, the stock had fallen 30%. At these levels, something had to give for AGN stock.

  • Pfizer Inc. Stock Is Boring, and That’s Perfect
    InvestorPlace2 months ago

    Pfizer Inc. Stock Is Boring, and That’s Perfect

    Pfizer Inc. (NYSE:PFE) reported earnings this morning and PFE stock is down on the news. Pfizer beat on the bottom line and boosts guidance. The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) has fallen 7% in about two weeks perhaps most influenced by combative remarks from President Trump vowing to continue fighting drug stocks and their management practices.

  • Forbes2 months ago

    Are ETFs A Safer Way To Invest In Biotech?

    After Cancer-Cure Makers Make Great Takeover Stocks was published in the October 24th issue of Forbes, a number of readers asked if there was a safe way to invest in biotech. Forbes reader Alice Lane asked the questions that seem to be on many people's minds. Here are my answers.

  • Barrons.com2 months ago

    Biotech Funds Bleeding Money

    Biotechnology stock funds, including the mutual and exchange-traded variety, suffered outflows of $382 million for the week ended Oct. 18. It's just a drop in the bucket given 101 funds have about $61 ...

  • Catch This Falling Knife — Go Long Celgene Corporation
    InvestorPlace2 months ago

    Catch This Falling Knife — Go Long Celgene Corporation

    Last night, Celgene Corporation (NASDAQ:CELG) released a headline that they canceled phase three for their potential solution to Crohn’s disease. The stock is now trading down 10%. This means that it would now be down 16% since early October.Source: Wikimedia (Modified)

  • MarketWatch2 months ago

    President Trump reiterates that drug companies 'getting away with murder' but says not much else

    President Donald Trump repeated rhetoric from early in his presidency about drug prices being "out of control" and drugmakers "getting away with murder" on Monday, but said nothing ...

  • Barrons.com2 months ago

    Biotech Fund Flows Turn Negative Ahead of Earnings

    Biotech's earnings season is right around the corner, and while some analysts may be bullish, Raymond James's Laura Chico writes that fund flows have taken a pause ahead of the reports. For the week ended October 11, biotech funds saw net outflows of $220 million, or a 0.36% decrease in assets, according to data  from Lipper/AMG Data Services, which covers 100 funds and about $61 billion in assets. Chico writes that this is the first week of outflows for the sector since the start of September.

  • ETF Trends2 months ago

    Hot Biotech Stocks, ETFs Can Keep Surging

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI), are up 29% and 49%, respectively, year-to-date. ...

  • Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow
    InvestorPlace2 months ago

    Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow

    Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.

  • Barrons.com2 months ago

    4 Biotechs to Buy Before Q3 Earnings

    With third-quarter earnings season upon us, Morgan Stanley’s Matthew Harrison and his team take a look at the biotech sector, writing that it will likely be a mixed bag for the group, but he's still bullish on several names. Harrison reiterated an Outperform rating on Alexion (ALXN), although he warns that he is below consensus on revenues.

  • How to trade biotech: 3 plays
    CNBC Videosyesterday

    How to trade biotech: 3 plays

    The "Fast Money" traders give you 3 ways to trade the biotech sector.